Drug intelligence / Profile preview

cefuroxime + clarithromycin

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

Cefuroxime + clarithromycin is a combination antibiotic therapy used primarily for treating respiratory tract infections, particularly community-acquired pneumonia (CAP). Cefuroxime is a second-generation cephalosporin antibiotic effective against many gram-positive and gram-negative bacteria. Clarithromycin is a macrolide antibiotic effective against atypical pathogens like Mycoplasma pneumoniae and Legionella pneumophila. The combination provides broad-spectrum coverage against common respiratory pathogens including Streptococcus pneumoniae.

Targets

PBP (Penicillin-binding protein family)Bacterial 50S ribosomal subunit

Beyond the preview

Go deeper on cefuroxime + clarithromycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cefuroxime + clarithromycin.

Explore the full profile